



Pharmacist-Led Comprehensive Medication Management (CMM) in Cardiovascular-Kidney-Metabolic (CKM) Disorders: Evidence-based Value Proposition

Created by Kate Dryden, PharmD, MBA

Patients with cardiovascular disease, chronic kidney disease, diabetes, and other metabolic conditions represent some of the most clinically complex encounters in healthcare. These patients require intensive medication management, frequent changes, and close monitoring—activities that consume significant time. They also account for a disproportionate share of total cost of care, hospital utilization, and performance risk in value-based contracts.

Pharmacist-led Comprehensive Medication Management (CMM) for persons with CKM syndrome is a strategic clinical infrastructure and high-return investment that can improve care quality while expanding physician capacity and clinic efficiency. CMM has been shown to reduce avoidable utilization, improve quality performance, and provide a positive return-on-investment (ROI).

The Operational Problem

- Persons with CKM are medically complex and require intensive medication management (initiation of GDMT, monitoring, dose titration, addressing drug interactions, and adverse effect management).
- These activities are time-intensive, poorly reimbursed, and a major contributor to provider burnout.^{1,2}
- As medication options expand, appropriate prescribing and monitoring require increasing expertise and follow-up intensity.³

The Financial Problem

- Patients with CKM disorders have high rates of preventable admissions and readmissions, experience frequent medication-related adverse events, and have high total cost of care.
- Lack of adequate medication management is an upstream driver of disease destabilization, emergency department visits, hospitalizations and accelerated progression of heart failure and chronic kidney disease.

The CMM Solution

Pharmacist-led CMM provides **longitudinal, accountable medication optimization**, including:

- Comprehensive review of all medications for appropriateness, effectiveness, safety, and adherence.
- Optimized medications across cardiovascular, kidney, and metabolic conditions, in the context of patients' other medical conditions and medications.
- Continued follow-up between physician visits, identifying and resolving medication-related problems to stabilize conditions and reduce risk of CKM progression.
- Enhancement of the patient experience by reducing need for multiple specialist visits (less travel and scheduling difficulties) and coordinated medication management and communication between patient's medical team members.

CMM is not just medication reconciliation—it is **ongoing clinical management of medication therapy**.

FFS Value Creation

1. Expands Physician Capacity

- Pharmacists absorb low-RVU, high-complexity medication-related work, freeing physicians to focus on diagnosis and procedural care with higher reimbursement.
- This improves schedule availability and increases throughput. Evidence shows pharmacist integration reduces clinician workload and stress while improving team efficiency.⁴

2. Improved Clinic Efficiency

- Shorter physician visit times for complex patients with numerous medication-related issues
- Fewer follow-up visits driven by unresolved medication issues.

3. Quality and Safety Benefits (Without Financial Risk Assumptions)

- Fewer adverse drug events and safer prescribing⁵
- Improved medication continuity across care transitions⁶

Clinical Quality & Financial Impact in Value-Based Models

1. Improved Quality Metric Performance

- Optimize blood pressure, A1c, and lipid control faster than when managed by non-pharmacist practitioners.^{7,8}
- Appropriate use of guideline-directed medication therapy and attainment of therapeutic goals.⁹
- Increased patient satisfaction with care.⁹

2. Reduced Utilization

- Fewer preventable hospitalizations and emergency department visits.¹⁰
- Lower 30-day readmission rates for heart failure.¹¹

3. Lower Total Cost of Care

- Reduced medication-related complications.⁵
- More appropriate and cost-effective use of high-cost therapies.⁵

Strategic Advantages

- Targets high-risk, high-cost populations in whom optimized medication management can yield an outsized return-on-investment over time to cover program implementation costs
- Scalable across ambulatory, specialty, and transitional care settings.
- Produces measurable, reportable outcomes aligned with payer contract requirements and population health dashboards.

1. Wolters Kluwer Health. Pharmacists on patient care teams are proving their value by streamlining workflow and drug decisions. Published May 30, 2025. Accessed March 6, 2026. <https://www.wolterskluwer.com/en/expert-insights/pharmacists-proving-their-value-streamlining-workflow-drug-decision>
2. White N. Reducing primary care provider burnout with pharmacist-delivered comprehensive medication management. *Am J Lifestyle Med.* 2021;15(2):133-135. Published online December 10, 2020. doi:10.1177/1559827620976539
3. Awdishu L, Maxson R, Gratt C, Rubenzik T, Battistella M. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: a primer on what pharmacists need to know. *Am J Health Syst Pharm.* 2025;82(12):660-671. doi:10.1093/ajhp/zxaf044
4. Hudson JQ, Chang AR, Condon Martinez AJ, Maxson R, Meaney CJ, St Peter WL. Optimizing comprehensive medication management in CKD: an opportunity to integrate pharmacists in the kidney care team. *Am J Kidney Dis.* 2026;87(3):433-442. doi:10.1053/j.ajkd.2025.09.024

5. Chung TH, Hernandez RJ, Libaud-Moal A, et al. Evaluation of comprehensive medication management for chronic diseases in primary care clinics in a Texas delivery system reform incentive payment program. *BMC Health Serv Res.* 2020;20(1):671. Published July 20, 2020. doi:10.1186/s12913-020-05537-3
6. The Joint Commission. *Transitions of Care: Managing Medications*. Quick Safety. Issue 26, Update. April 2022.
<https://digitalassets.jointcommission.org/api/public/content/f2bc2df2b9f145859c01e8941e70b282?v=413a59d6>
7. Rodriguez de Bittner M, Chirikov VV, Breunig IM, Zaghab RW, Shaya FT. Clinical effectiveness and cost savings in diabetes care supported by pharmacist counseling. *J Am Pharm Assoc (2003)*. 2017;57(1):102-108.e4. doi:10.1016/j.japh.2016.08.010
8. Greer N, Bolduc J, Geurkink E, et al. Pharmacist-led chronic disease management: a systematic review of effectiveness and harms compared with usual care. *Ann Intern Med.* 2016;165(1):30-40. doi:10.7326/M15-3058
9. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. *Ann Intern Med.* 2007;146(10):714-725. PMID:17502632
10. Moczygemba LR, Alshehri AM, Harlow LD III, et al. Comprehensive health management pharmacist-delivered model: impact on health care utilization and costs. *Am J Manag Care.* 2019;25(11):554-560.
11. Hahn L, Belisle M, Nguyen S, Snackey Alvarez K, Das S. Effect of pharmacist clinic visits on 30-day heart failure readmission rates at a county hospital. *Hosp Pharm.* 2019;54(6):358-364. doi:10.1177/0018578718797263